Association of Pertuzumab, Trastuzumab, and Docetaxel Combination Therapy With Overall Survival in Patients With Metastatic Breast Cancer.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 33439261.
- Also identified by DOI 10.1001/jamanetworkopen.2020.27764 and PMC identifier 7807287.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This cohort study compares the findings of combined pertuzumab, trastuzumab, and docetaxel therapy in women with metastatic breast cancer with those in the CLEOPATRA trial.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- Breast Neoplasms
- Docetaxel
- Trastuzumab